Zenith Drugs Ltd (ZDL) is like that neighbourhood chemist who suddenly decided to play IPL auctions. Incorporated in 2000, listed on NSE SME in Feb 2024, and already juggling tenders from half the state governments of India, plus random countries like Sierra Leone and Bhutan. Market cap? ₹124 Cr – which is basically small enough for Sun Pharma’s CFO to misplace in his weekend golf bets. The company has sales of ₹133 Cr, profit of ₹7 Cr, and debt of ₹49 Cr – i.e. one wrong batch of paracetamol and the bank manager will start practising his recovery calls.
2. Introduction
Picture this: A pharma company in Indore that claims WHO GMP compliance, 250 molecules, 780 SKUs, exports to 8 countries, but still trades at just ₹72/share. Sounds like “international reach, local bechaari.”
Zenith Drugs runs a medicine business that’s like a Gujarati thali – everything included: oral powders, ointments, syrups, tablets, capsules, injectables, creams. You want ORS? They’ll ship it. You want Albendazole for animals? They’ve got it. You want Ketoconazole shampoo for your dandruff? They’ll even get the Ministry of Defence to use it.
But here’s the kicker: they live off tenders. Rajasthan, Madhya Pradesh, Gujarat, MoD – everyone is sending them supply orders like shaadi ka buffet caterer. That means lumpy revenues, high receivables (166 debtor days, lol), and boardroom prayers before tender announcements.
They even did an SME IPO in Feb 2024 – raised ₹40 Cr, bought machinery, upgraded blocks, and promised investors “new units and growth.” Result? Stock listed at ₹154, now at ₹72. Half gone. Investors? “Humse na ho payega.”
3. Business Model – WTF Do They Even Do?
Think of ZDL as the contractor doctor for half of India’s government hospitals. They don’t run fancy branded drugs like Sun or Cipla. Instead, they churn out affordable generics, ointments, and syrups – bulk-supply style.
Revenue split FY24:
Oral Powders – 22% (ORS sachet kings of Madhya Pradesh)
Ointments/Creams – 25%
Capsules – 9%
Liquid Externals – 44%
Revenue streams:
Sale of products – 73%
Trading sales – 25% (because apparently, making isn’t enough, they also flip products like a Kirana store)
Interest & royalty – 2%
Clientele: Ajanta Pharma, Micro Labs, Troikaa – basically bigger cousins who outsource their petty work.
Geography: 18+ Indian states and exports to exotic addresses like Liberia, Sierra Leone, and Costa Rica. (Basically, they found markets where Sun Pharma doesn’t bother showing up.)
Subsidiary: My Med Pvt Ltd – but board already approved its sale. Classic SME move: create a sub, milk it, sell it.
